Showing results (161-170 of 272) with videos related to
Sort By:
Pageof 28
Clinical Nuclear Medicine|January 10, 2012
Radioguided surgery in neuroendocrine tumors using Ga-68-labeled somatostatin analogs: a pilot studyDaniel Kaemmerer, Vikas Prasad, Wolfgang Daffner, et al.Scientific Reports|July 26, 2019
Accuracy of standard clinical 3T prostate MRI for pelvic lymph node staging: Comparison to 68Ga-PSMA PET-CTSebastian Meißner, Jan-Carlo Janssen, Vikas Prasad, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 18, 2012
Combined 18F-fluoride and 18F-FDG PET/CT scanning for evaluation of malignancy: results of an international multicenter trialAndrei Iagaru, Erik Mittra, Camila Mosci, et al.Analytical Chemistry|February 15, 2017
In Vitro Functional Quality Characterization of NOTA-Modified SomatropinsNathalie Bracke, Han Yao, Evelien Wynendaele, et al.Molecular Imaging and Biology|December 8, 2023
The Theranostic Optimization of PSMA-GCK01 Does Not Compromise the Imaging Characteristics of [99mTc]Tc-PSMA-GCK01 Compared to Dedicated Diagnostic [99mTc]Tc-EDDA/HYNIC-iPSMA in Prostate CancerEduards Mamlins, Lara Scharbert, Jens Cardinale, et al.Seminars in Nuclear Medicine|October 8, 2025
Advances in Dosimetry and Imaging for 203Pb and 212Pb RadiotheranosticsKeamogetswe Ramonaheng, Milani Qebetu, Kaluzi Banda, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 21, 2010
Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled affibody moleculesRichard P Baum, Vikas Prasad, Dirk Müller, et al.International Journal of Clinical and Experimental Pathology|May 5, 2012
Comparing of IRS and Her2 as immunohistochemical scoring schemes in gastroenteropancreatic neuroendocrine tumorsDaniel Kaemmerer, Luisa Peter, Amelie Lupp, et al.European Journal of Nuclear Medicine and Molecular Imaging|August 16, 2019
Prognostic Significance of Somatostatin Receptor Heterogeneity in Progressive Neuroendocrine Tumor Treated with Lu-177 DOTATOC or Lu-177 DOTATATEJosephine Graf, Ulrich-Frank Pape, Henning Jann, et al.Current Problems in Cancer|September 4, 2024
Theranostics in Neuroendocrine Tumors: Updates and Emerging TechnologiesNadine Mallak, Burcak Yilmaz, Catherine Meyer, et al.Pageof 28